Köfalvi, Attila
Moreno, Estefanía
Cordomí, Arnau
Cai, Ning-Sheng
Fernández-Dueñas, Victor
Ferreira, Samira G.
Guixà-González, Ramón
Sánchez-Soto, Marta
Yano, Hideaki
Casadó-Anguera, Verònica
Cunha, Rodrigo A.
Sebastião, Ana Maria
Ciruela, Francisco
Pardo, Leonardo
Casadó, Vicent
Ferré, Sergi http://orcid.org/0000-0002-1747-1779
Funding for this research was provided by:
National Institute on Drug Abuse (Intramural funds)
Dirección General de Universidades e Investigación (SAF2015-74627-JIN, SAF2016-77830-R, SAF2017-87349-R)
Fundação para a Ciência e a Tecnologia (PTDC/DTP-FTO/3346/2014 and PTDC/MED-NEU/31274/2017)
Catalan Government (2017 SGR 1604)
Article History
Received: 10 October 2019
Accepted: 13 January 2020
First Online: 23 January 2020
Ethics approval
: All studies with animal preparations were conducted in accordance with the principles and procedures outlined as “3Rs” in the guidelines of EU (86/609/EEC), FELASA, and the National Centre for the 3Rs (Kilkenny et al., Brit. J. Pharmacol.; 2010, 160: 1577-1579), and were approved by the Animal Care Committee of the Center for Neuroscience and Cell Biology of the University of Coimbra, Portugal. All efforts were made to minimize the number of animals used and to minimize their stress and discomfort.
: Not applicable
: The authors declare that they have no competing interests.